216 related articles for article (PubMed ID: 35994791)
1. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM).
Ciardiello D; Chiarazzo C; Famiglietti V; Damato A; Pinto C; Zampino MG; Castellano G; Gervaso L; Zaniboni A; Oneda E; Rapisardi S; Bordonaro R; Zichi C; De Vita F; Di Maio M; Parisi A; Giampieri R; Berardi R; Lavacchi D; Antonuzzo L; Tamburini E; Maiorano BA; Parrella P; Latiano TP; Normanno N; De Stefano A; Avallone A; Martini G; Napolitano S; Troiani T; Martinelli E; Ciardiello F; De Vita F; Maiello E
ESMO Open; 2022 Oct; 7(5):100567. PubMed ID: 35994791
[TBL] [Abstract][Full Text] [Related]
2. Real-world first-line treatment of patients with BRAF
Martinelli E; Cremolini C; Mazard T; Vidal J; Virchow I; Tougeron D; Cuyle PJ; Chibaudel B; Kim S; Ghanem I; Asselain B; Castagné C; Zkik A; Khan S; Arnold D
ESMO Open; 2022 Dec; 7(6):100603. PubMed ID: 36368253
[TBL] [Abstract][Full Text] [Related]
3. [The efficacy of chemotherapy re-challenge in third-line setting for metastatic colorectal cancer patients: a real-world study].
Duan JJ; Ning T; Bai M; Zhang L; Li HL; Liu R; Ge SH; Wang X; Yang YC; Ji Z; Wang FX; Sun YS; Ba Y; Deng T
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):967-972. PubMed ID: 37968083
[No Abstract] [Full Text] [Related]
4. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Liu X; Ou K; Ma X; Gao L; Wang Q; Zhang H; Yang L
BMC Cancer; 2022 Jul; 22(1):807. PubMed ID: 35864467
[TBL] [Abstract][Full Text] [Related]
6. CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.
Shi Y; Li J; Xu J; Sun Y; Wang L; Cheng Y; Liu W; Sun G; Chen Y; Bai L; Zhang Y; He X; Luo Y; Wang Z; Liu Y; Yao Q; Li Y; Qin S; Hu X; Bi F; Zheng R; Ouyang X
Cancer Commun (Lond); 2019 May; 39(1):28. PubMed ID: 31126331
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS
Formica V; Morelli C; Conca V; Calegari MA; Lucchetti J; Dell'Aquila E; Schirripa M; Messina M; Salvatore L; Lo Prinzi F; Dima G; Trovato G; Riondino S; Roselli M; Skoulidis F; Arkenau HT; Cremolini C
Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37297026
[TBL] [Abstract][Full Text] [Related]
8. Tumour location and efficacy of first-line EGFR inhibitors in
Benavides M; Díaz-Rubio E; Carrato A; Abad A; Guillén C; Garcia-Alfonso P; Gil S; Cano MT; Safont MJ; Gravalos C; Manzano JL; Sánchez A; Alcaide J; López R; Massutí B; Sastre J; Martínez E; Escudero P; Méndez M; Aranda E
ESMO Open; 2019; 4(6):e000599. PubMed ID: 31803504
[TBL] [Abstract][Full Text] [Related]
9. Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
Parisi A; Porzio G; Cannita K; Venditti O; Avallone A; Filippi R; Salvatore L; Tortora G; Ribelli M; Nigro O; Gelsomino F; Spallanzani A; Zurlo V; Leo S; Dell'Aquila E; Claudia F; Lombardi P; Keränen SR; Aimar G; Depetris I; Giampieri R; Morelli C; De Tursi M; Tinari N; Di Pietro FR; De Galitiis F; Zanaletti N; Troiani T; Vitale P; Garajova I; Ghidini M; Spinelli GP; Zoratto F; Roberto M; Ierino D; Petrillo A; D'Orazio C; Ficorella C; Cortellini A
Clin Colorectal Cancer; 2021 Dec; 20(4):318-325. PubMed ID: 34380594
[TBL] [Abstract][Full Text] [Related]
10. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
11. Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11).
Sunakawa Y; Satake H; Usher J; Jaimes Y; Miyamoto Y; Nakamura M; Kataoka M; Shiozawa M; Takagane A; Terazawa T; Watanabe T; Ishiguro K; Tanaka C; Takeuchi M; Fujii M; Danenberg K; Danenberg PV; Lenz HJ; Sekikawa T; Ichikawa W
ESMO Open; 2022 Jun; 7(3):100512. PubMed ID: 35688061
[TBL] [Abstract][Full Text] [Related]
12. Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis.
Tian M; Li H; Dong W; Li Y; Jiang T; Lv Y; Zeng J; Jiang X; Yin Z; Xiao J
World J Surg Oncol; 2023 Nov; 21(1):355. PubMed ID: 37978547
[TBL] [Abstract][Full Text] [Related]
13. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated
Tabernero J; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Elez E; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
J Clin Oncol; 2021 Feb; 39(4):273-284. PubMed ID: 33503393
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study.
Jiang T; Chen H; Zheng J; Du B; Yang B; Liu Q; Zhong D; Wang X; Wang H; Lin M; Lai J; Hou P; Lin X
Adv Ther; 2020 Jun; 37(6):2829-2840. PubMed ID: 32378072
[TBL] [Abstract][Full Text] [Related]
15. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
[TBL] [Abstract][Full Text] [Related]
17. WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAF
Shimozaki K; Hirata K; Sato T; Nakamura M; Kato K; Hirano H; Kumekawa Y; Hino K; Kawakami K; Kito Y; Matsumoto T; Kawakami T; Komoda M; Nagashima K; Sato Y; Yamazaki K; Hironaka S; Takaishi H; Hamamoto Y; Muro K
Clin Colorectal Cancer; 2022 Dec; 21(4):339-346. PubMed ID: 36117091
[TBL] [Abstract][Full Text] [Related]
18. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
Tougeron D; Sueur B; Zaanan A; de la Fouchardiére C; Sefrioui D; Lecomte T; Aparicio T; Des Guetz G; Artru P; Hautefeuille V; Coriat R; Moulin V; Locher C; Touchefeu Y; Lecaille C; Goujon G; Ferru A; Evrard C; Chautard R; Gentilhomme L; Vernerey D; Taieb J; André T; Henriques J; Cohen R;
Int J Cancer; 2020 Jul; 147(1):285-296. PubMed ID: 31970760
[TBL] [Abstract][Full Text] [Related]
19. Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice.
Kazama K; Shiozawa M; Numata M; Sugano N; Sato S; Uchiyama M; Sato M; Aoyama T; Tamagawa H; Oshima T; Yukawa N; Rino Y
Int J Colorectal Dis; 2022 Feb; 37(2):337-348. PubMed ID: 34767074
[TBL] [Abstract][Full Text] [Related]
20. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
